Global Patent Index - EP 4294789 A1

EP 4294789 A1 20231227 - COMPOSITIONS OF ESSENTIALLY PURE FORM IV OF N-((R)-2,3- DIHYDROXYPROPOXY)-3,4-DIFLUORO-2- (2-FLUORO-4-IODOPHENYLAMINO)- BENZAMIDE AND USES THEREOF

Title (en)

COMPOSITIONS OF ESSENTIALLY PURE FORM IV OF N-((R)-2,3- DIHYDROXYPROPOXY)-3,4-DIFLUORO-2- (2-FLUORO-4-IODOPHENYLAMINO)- BENZAMIDE AND USES THEREOF

Title (de)

ZUSAMMENSETZUNGEN DER IM WESENTLICHEN REINEN FORM IV VON N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUOR-2- (2-FLUOR-4-IODOPHENYLAMINO)-BENZAMID UND IHRE VERWENDUNG

Title (fr)

COMPOSITIONS DE FORME IV ESSENTIELLEMENT PURE DE N-((R)-2,3-DIHYDROXYPROPOXY)-3,4-DIFLUORO-2-(2-FLUORO-4-IODOPHÉNYLAMINO)-BENZAMIDE ET LEURS UTILISATIONS

Publication

EP 4294789 A1 20231227 (EN)

Application

EP 21710827 A 20210217

Priority

US 2021018378 W 20210217

Abstract (en)

[origin: WO2022177556A1] The present disclosure relates to: a) a crystalline composition of essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide; b) pharmaceutical compositions comprising the crystalline composition of essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide, and, optionally, a pharmaceutically acceptable carrier; and c) methods of treating a tumor, a cancer, or a Rasopathy disorder by administering the crystalline composition of essentially pure Form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide to a subject in need thereof.

IPC 8 full level

C07C 259/10 (2006.01); A61K 31/166 (2006.01); A61P 35/00 (2006.01)

CPC (source: EP IL KR)

A61K 9/20 (2013.01 - KR); A61K 9/48 (2013.01 - KR); A61K 31/166 (2013.01 - EP IL KR); A61K 47/12 (2013.01 - KR); A61K 47/38 (2013.01 - KR); A61P 35/00 (2018.01 - EP IL KR); C07C 259/10 (2013.01 - EP IL KR); C07B 2200/13 (2013.01 - KR)

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2022177556 A1 20220825; AR 124907 A1 20230517; AU 2021428932 A1 20230921; CA 3211395 A1 20220825; CN 117500781 A 20240202; EP 4294789 A1 20231227; IL 304974 A 20231001; JP 2024507822 A 20240221; KR 20230148177 A 20231024; MX 2023009555 A 20231110; TW 202245746 A 20221201

DOCDB simple family (application)

US 2021018378 W 20210217; AR P220100332 A 20220217; AU 2021428932 A 20210217; CA 3211395 A 20210217; CN 202180095226 A 20210217; EP 21710827 A 20210217; IL 30497423 A 20230806; JP 2023549999 A 20210217; KR 20237030268 A 20210217; MX 2023009555 A 20210217; TW 111105793 A 20220217